

Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Graham Collins¹, Steven Horwitz², Mehdi Hamadani³, Felipe Samaniego⁴, Alexander Spira⁵, Paolo Caimi⁶, Andrew Davies⁷, Tobias Menne⁸, Paul Fields⁹, Hans Cruz¹⁰, Shui He¹¹, Joseph Boni¹¹, Jay Feingold¹¹, Jens Wuerthner¹⁰, John Radford¹²

¹Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; ²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁵Virginia Cancer Specialists Research Institute, Fairfax, VA, USA; ⁶University Hospitals Cleveland Medical Center, Case Western Reserve University (CWRU), Cleveland, OH, USA; ⁷Cancer Research UK Centre, University of Southampton, Southampton, UK; ⁸Department of Haematology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; ⁹Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK; ¹⁰ADC Therapeutics SA, Epalinges, Switzerland; ¹¹ADC Therapeutics, Murray Hill, NJ, USA; ¹²Department of Medical Oncology, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

15th International Conference on Malignant Lymphoma

June 18–22, 2019, Lugano, Switzerland

Conflict of Interest Disclosures



Graham Collins

Honoraria: ADC Therapeutics, Roche, MSD, Gilead, Celleron Therapeutics, Takeda, BMS

Research funding: MSD, Celleron Therapeutics, Celgene, Amgen, ADC Therapeutics, Pfizer, BMS


Acknowledgments

**The authors would like to thank all the participating patients and their families,
all study co-investigators, and research coordinators**

Study sponsored by ADC Therapeutics SA ([NCT02432235](#))

Editorial support was provided by Fishawack Communications Ltd

Structure and components of camidanlumab tesirine (Cami)




Immunological rationale

- Targeting of CD25+ Tregs may increase the Teff:Treg → immunologic tumour eradication¹
- Anti-CD25 therapies synergise with PD-1 blockade to eradicate established tumours²

Mode of action

1. Cami binds to the CD25 antigen on the tumor cell surface
2. ADC internalisation, linker cleavage, and PBD release
3. Cytotoxic DNA cross-link formation
4. Stalled DNA replication fork causing cell death^{3,4}



1. Sasidharan NV, et al. *Immunol Cell Biol.* 2018;96:21–33. 2. Arce Vargas F, et al. *Immunity.* 2017;46:577–86. 3. Hartley JA. *Expert Opin Investig Drugs.* 2011;20:733–44. 4. Flynn MJ, et al. *Mol Cancer Ther.* 2016;15:2709–21.

ADC, antibody drug conjugate; CD25, cluster of differentiation 25; PBD, pyrrolobenzodiazepine; Teff, effector T cell; Treg, regulatory T cell; Val-Ala, valine-alanine..

Phase 1 Study in Patients With Histologically Confirmed R/R NHL or cHL



STUDY DESIGN

- **Part 1:** Dose escalation; continual reassessment method
 - **Part 2:** Dose expansion
- 1-hour intravenous infusion (3–300 µg/kg); once every 3 weeks (Q3W)

PRIMARY OBJECTIVE

Evaluate safety and tolerability and determine the MTD/RDE of camidanlumab tesirine

KEY INCLUSION CRITERIA FOR PATIENTS WITH cHL

- Male or female aged 18 years or older
- ECOG Performance Status 0 to 2
- Failed, or intolerant to, any established therapy known to provide clinical benefit at current state of disease
- Prior treatment with brentuximab vedotin and CHPi*

For cHL population: Enrollment complete. MTD not reached; 2 RDEs for Part 2, 30 and 45 µg/kg Q3W
For NHL population: Enrollment of patients with T-cell lymphoma continues in Part 2 at 80 µg/kg Q3W

*Introduced with Amendment 7 (Jan 2018). cHL, classical Hodgkin lymphoma; CHPi, checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group; MTD, maximum tolerated dose; NHL, non-Hodgkin lymphoma; RDE, recommended dose for expansion; R/R, relapsed/refractory.

Camidanlumab Tesirine in Classical Hodgkin Lymphoma

Patient Characteristics



Patient Baseline Characteristics All Lymphoma Types	Total (N=128*)
Sex, n (%)	
Female	52 (40.6)
Male	76 (59.4)
Race, n (%)	
White	104 (81.3)
Black or African American	14 (10.9)
Asian	4 (3.1)
Other	6 (4.7)
Age, years, median (min, max)	52 (19, 88)
Number of previous systemic therapies, median (min, max)	5 (1, 15)
Prior stem cell transplant, n (%)	57 (44.5)

Previous systemic therapies included prior SCT. *Safety analysis set.
DLBCL, diffuse large B-cell lymphoma; SCT, stem cell transplantation.

Patient Diagnosis at Baseline	N (%)
All patients*	128
Classical Hodgkin lymphoma	77 (60.2)
DLBCL	14 (10.9)
Mantle cell lymphoma	3 (2.3)
Burkitt lymphoma	1 (0.8)
Mediastinal (thymic) large B-cell lymphoma	1 (0.8)
Follicular lymphoma	1 (0.8)
Cutaneous T-cell lymphoma	13 (10.2)
Peripheral T-cell lymphoma	5 (3.9)
Adult T-cell leukemia/lymphoma	8 (6.3)
Angioimmunoblastic T-cell lymphoma	2 (1.6)
Other	3 (2.3)

Data shown as of Apr 14, 2019.

cHL Population: Selected Toxicities Summary, All Grades

Potentially PBD-Related TEAEs (SMQ), n (%)*	30 µg/kg (n=20)	45 µg/kg (n=37)	Total (N=77)
Edema or effusion	5 (25.0)	10 (27.0)	19 (24.7)
Skin related	10 (50.0)	25 (67.6)	50 (64.9)
Liver function test	2 (10.0)	13 (35.1)	30 (39.0)
Selected autoimmune and neurologic toxicities, n (%)*			
Peripheral sensory neuropathy	1 (5.0)	5 (13.5)	7 (9.1)
Guillain–Barré syndrome/radiculopathy	1 (5.0)	3 (8.1)	5 (6.5)
Colitis	0	1 (2.7)	2 (2.6)
Hypothyroidism	0	2 (5.4)	4 (5.2)
Hyperthyroidism	0	2 (5.4)	2 (2.6)
Pneumonitis	0	0	1 (1.3)
Thyroiditis	0	0	1 (1.3)

One additional patient died of multiple cranial nerve palsy/polyneuropathy considered possibly related to camidanlumab tesirine, but this patient received two cycles of BV after camidanlumab tesirine and prior to symptom deterioration

cHL Population: Most Common ($\geq 5\%$ Total) Grade ≥ 3 TEAEs

TEAEs, n (%)*	30 µg/kg (n=20)	45 µg/kg (n=37)	Total (N=77)
Patients with any Grade ≥ 3 TEAEs	12 (60.0)	25 (67.6)	51 (66.2)
GGT increased	2 (10.0)	3 (8.1)	13 (16.9)
Maculopapular rash	2 (10.0)	8 (21.6)	13 (16.9)
ALT increased	0 (0.0)	3 (8.1)	7 (9.1)
Anemia	2 (10.0)	3 (8.1)	6 (7.8)
AST increased	0 (0.0)	1 (2.7)	5 (6.5)
Guillain–Barré syndrome/radiculopathy	1 (5.0)	3 (8.1)	5 (6.5)
Lipase increased	1 (5.0)	3 (8.1)	4 (5.2)
Patients with any TEAEs leading to treatment discontinuation, (%)	20.0	27.0	26.0


*Only 1 Grade 5 event (death) due to unspecified cause was reported in the 45 µg/kg treatment group.

The most common all grade TEAEs ($\geq 20\%$) in the total cHL population were fatigue, maculopapular rash, pyrexia, GGT increased, nausea, ALT increased, AST increased, and cough

Data shown as of Apr 14, 2019. Safety analysis set. For each preferred term, patients are included only once.


ALT, alanine aminotransferase; AST, aspartate aminotransferase; cHL, classical Hodgkin lymphoma; GGT, gamma-glutamyltransferase; TEAE, treatment-emergent adverse event.

cHL Population: Response Rates (Lugano Classification 2014)



Data shown as of Apr 14, 2019. Efficacy analysis set. Data are presented as % of patients that showed complete response, partial response, stable disease, or progressive disease in different groups. cHL, classical Hodgkin lymphoma; ORR, overall response rate.

cHL Population: Late Responses Without Further Dosing



4 patients had improved responses to camidanlumab tesirine ≥ 6 weeks after their last infusion


Data shown as of Apr 14, 2019. Efficacy analysis set. Each bar represents 1 patient in the study. *Only for censored patients who discontinued due to reasons other than progression or who go onto a different anticancer treatment. cHL, classical Hodgkin lymphoma.

cHL Population: Response Rates by Clinical Characteristics

Characteristic	Subgroups	45 µg/kg Cohort (N=37)	
		ORR n/N, %	CR n/N, %
Overall	–	32/37, 86.5	18/37, 48.6
Age group, years	≤55	25/28, 89.3	14/28, 50.0
	>55	7/9, 77.8	4/9, 44.4
Disease stage at study entry	I–II	12/14, 85.7	8/14, 57.1
	III	8/8, 100.0	5/8, 62.5
	IV	12/15, 80.0	5/15, 33.3
Number of prior therapies	<4	6/6, 100.0	3/6, 50.0
	≥4	26/31, 83.9	15/31, 48.4
Response to first-line systemic anticancer therapy	Refractory	11/13, 84.6	6/13, 46.2
	Relapsed	21/24, 87.5	12/24, 50.0
Response to most recent prior systemic anticancer therapy	Refractory	22/25, 88.0	11/25, 44.0
	Relapsed	8/10, 80.0	6/10, 60.0

Data shown as of Apr 14, 2019. Efficacy analysis set. Dark blue: Similar CR rate irrespective of variable. Purple: Trend for reduced CR rate in refractory patients compared with relapsed patients; confirmed by PK modeling (next slide).
cHL, classical Hodgkin lymphoma; CR, complete response; ORR, overall response rate; PK, pharmacokinetic.


Probability of Objective Response vs C_{max} in Patients With cHL Receiving Camidanlumab Tesirine



- Median exposures from 30 to 60 $\mu\text{g/kg}$ increased and indicated a positive exposure-response relationship
- Mean predicted probabilities of response for typical patients were 0.87 for relapsed and 0.67 for refractory patients

Graphics depict mean and 95% confidence intervals of predicted probabilities. Coloured numbers denote the dose ($\mu\text{g/kg}$) groups administered; yellow diamonds and vertical dotted lines denote the median respective exposures. P-value is overall significance of model with predictors compared with intercept alone. Ab, antibody; cHL, classical Hodgkin lymphoma; C_{max} , concentration maximum; PBD, pyrrolbenzodiazepine.

cHL Population: Responses by Prior CHPi (45 µg/kg Cohort): Safety and Efficacy



Selected TEAE Groups, n (%) [†]	45 µg/kg Cohort (N=37)		
	≤4 Months (n=15)	>4 Months (n=11)	None (N=11)
Edema or effusion	5 (33.3)	2 (18.2)	3 (27.3)
Liver function test	6 (40.0)	4 (36.4)	3 (27.3)
Skin related	10 (66.7)	8 (72.7)	7 (63.6)
Autoimmune	5 (33.3)	4 (36.4)	2 (18.2)
Neurologic	4 (26.7)	3 (27.3)	3 (27.3)
Guillain–Barré syndrome/radiculopathy [‡]	1 (6.7)	1 (9.1)	1 (9.1)

Data shown as of Apr 14, 2019. For each common adverse event group and preferred term in table, patients are included only once at the maximum severity. *Efficacy analysis set. †Safety analysis set. ‡Two other events occurred at 30 and 60 µg/kg doses in the >4 months and none groups, respectively.

CHPi, checkpoint inhibitor; CR, complete response; ORR, overall response rate; PR, partial response; TEAE, treatment-emergent adverse event.

Conclusions

The recommended dose for Phase 2 in cHL (NCT02432235) has been determined as 45 µg/kg Q3W dosed for two cycles (optimal ORR), followed by 30 µg/kg Q3W (to improve tolerability while maintaining significant anticancer activity)

ORR to camidanlumab tesirine was high across all subgroups, suggesting **robust antitumour activity across the R/R cHL population**

Significant difference in relapsed (higher predicted probability of response) vs refractory to last line of therapy was seen in PK modeling

Reported cases of Guillain–Barré syndrome/radiculopathy did not appear related to prior CHPi